Three-dimensional quantitative structure-activity relationship studies on c-src inhibitors based on different docking methods

Chemical Biology and Drug Design

Volumn 73, Issue 4, 2009, Pages 416-427

  Bairy, Santhosh Kumar ^a   Suneel Kumar, B V S ^a   Bhalla, Joseph Uday Tej ^a   Pramod, A B ^a   Ravikumar, Muttineni ^a  

^a Biocampus   (India)

Author keywords

3D QSAR; C Src kinase; Docking; Quinazolin derivatives; Receptor based alignment

Indexed keywords

PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DESIGN; ENZYME INHIBITION; MOLECULAR MODEL; ONCOGENE SRC; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

CATALYTIC DOMAIN; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINAZOLINES;

EID: 61849185822     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00789.x     Document Type: Article

References (49)

1. Schwartzberg P.L. (1998) The many faces of Src: multiple functions of a prototypical tyrosine kinase. Oncogene 17 : 1463 1468.
2. Abram C.L., Courtneidge S.A. (2000) Src family tyrosine kinases and growth factor signaling. Exp Cell Res 254 : 1 13.
3. Biscardi J.S., Tice D.A., Parsons S.J. (1999) c-Src, receptor tyrosine kinases, and human cancer. Adv Can Res 76 : 61 119.
4. Boschelli D.H., Boschelli F. (2000) Small molecule inhibitors of Src family kinases. Drugs Future 25 : 717 736.
5. Weis S., Shintani S., Weber A., Kirchmair R., Wood M., Cravens A., McSharry H., Iwakura A., Yoon Y., Himes N., Burstein D., Doukas J., Soll R., Losordo D., Cheresh D.A. (2004) Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction, D. J Clin Invest 113 : 885 894.
6. Paul R., Zhang Z.G., Eliceiri B.P., Jiang Q., Boccia A.D., Zhang R.L., Chopp M., Cheresh D.A. (2001) Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med 7 : 222 227.
7. Susva M., Missbach M., Green J. (2000) Src inhibitors: drugs for the treatment of osteoporosis, cancer or both? Trends Pharmacol Sci 21 : 489 495.
8. Yeatman T.J. (2004) A renaissance for SRC. Nat Rev 4 : 470 480.
9. Talamonti M.S., Roh M.S., Curley S.A., Gallick G.E. (1993) Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91 : 53 60.
10. Wiener J.R., Windham T.C., Estrella V.C., Parikh N.U., Thall P.F., Deavers M.T., Bast R.C., Mills G.B., Gallick G.E. (2003) Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88 : 73 79.
11. Ito H., Gardner-Thorpe J., Zinner M.J., Ashley S.W., Whang E.E. (2003) Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 134 : 221 226.
12. Summay J.M., Gallick G.E. (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22 : 337 358.
13. Irby R.B., Yeatman T.J. (2000) Role of Src expression and activation in human cancer. Oncogene 19 : 5636 5642.
14. Frame M.C. (2002) Src in cancer: deregulation and consequences for cell behavior. Biochim Biophys Acta 1602 : 114 130.
15. Martin G.S. (2001) The hunting of the Src. Nat Rev Mol Cell Biol 2 : 467 475.
16. Summy J.M., Gallick G.E. (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22 : 337 358.
17. Courtneidge S.A. (2002) Role of Src in signal transduction pathways. Biochem Soc Trans 30 : 11 17.
18. Schroeder M.C., Hamby J.M., Connolly C.J.C., Grohar P.J., Winters R.T., Barvian M.R., Moore C.W. et al. (2001) Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. J Med Chem 44 : 1915 1926.
19. -src. J Med Chem 43 : 3134 3147.
20. Berger D., Dutia M., Powell D., Wissner A., DeMorin F., Raifeld Y., Weber J., Boschelli F. (2002) Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors. Bioorg Med Chem Lett 12 : 2989.
21. Boschelli D.H., Wang Y.D., Biqi Wu F.Y., Zhang N., Dutia M., Powell D.W., Wissner A., Arndt K., Weber J.M., Boschelli F. (2001) Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J Med Chem 44 : 822 833.
22. Thaimattam R., Daga P.R., Banerjee R., Iqbal J. (2005) 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases Bio. Med Chem 13 : 4704.
23. Boschelli D.H., Wang Y.D., Johnson S., Wu B., Ye F., Barrios Sosa A.C., Golas J.M., Boschelli F. (2004) 7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases. J Med Chem 47 : 1599 1601.
24. La Rosee P., Corbin A.S., Stoffregen E.P., Deininger M.W., Druker B.J. (2002) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate. Cancer Res 62 : 7149 7153.
25. Huron D.R., Gorre M.E., Kraker A.J., Sawyers C.L., Rosen N., Moasser M.M. (2003) A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 9 : 1267 1273.
26. Ple P.A., Green T.P., Hennequin L.F., Curwen J., Fennell M., Allen J., Lambert-van der Brempt C., Costello G. (2004) Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 47 : 871 887.
27. Hennequin L.F., Allen J., Costello G.C., Curwen J., Fennell M., Green T.P., Jacobs V., Lambert-van der Brempt C., Morgentin R., Olivier A., Ple P.A., Whittaker R. (2003). Proc Am Assoc Cancer Res (abstract B193).
28. Boschelli D.H., Ye F., Wang Y.D., Dutia M., Johnson S.L., Wu B., Miller K. et al. (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 44 : 3965 3977.
29. Golas J.M., Arndt K., Etienne C., Lucas J., Nardin D., Gibbons J., Frost P., Ye F., Boschelli D.H., Boschell F. (2003) SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63 : 375 381.
30. Golas J.M., Lucas J., Etienne C., Golas J., Discafani C., Sridharan L., Boghaert E., Arndt K., Ye F., Boschelli D.H., Li F., Titsch C., Huselton C., Chaudhary I., Boschelli F. (2005) SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft. Models Cancer Res 65 : 5358 5364.
31. Shah N.P., Tran C., Lee P., Chen P., Norris D., Sawyers C.L. (2004) Overriding imatinib resistance with a novel Abl kinase inhibitor. Science 305 : 399 401.
32. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., Castaneda S. et al. (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2- hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-arboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47 : 6658 6661.
33. Miller M.D., Sheridan R.P., Kearsley S.K. (1992) sq: a program for rapidly producing pharmacophorically relevent molecular superpositions. J Med Chem 42 : 1505 1514.
34. Lemmen C., Lengauer T. (2000) Computational methods for the structural alignment of molecules. J Comput Aided Mol Des 14 : 215 232.
35. Jain A.N. (2004) Ligand-based structural hypotheses for virtual screening. J Med Chem 47 : 947 961.
36. Hansch C., Leo A. (1995) Exploring QSAR. Fundamentals and Applications in Chemistry and Biology. Washington, DC : American Chemical Society.
37. Kubinyi H. (1997) QSAR and 3D QSAR in drug design. Drug Discov Today 1997 : 2.
38. Cramer R.D., III., Patterson D.E., Bunce J.D. (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110 : 5959 5967.
39. Cho S.J., Tropsha A. (1995) Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. J Med Chem 38 : 1060 1066.
40. Halgren T.A. (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17 : 490 519.
41. Halgren T.A. (1996) Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J Comput Chem 17 : 520 552.
42. Halgren T.A. (1996) Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94. J Comput Chem 17 : 553 586.
43. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., Shenkin P.S. (2004) Glide: a new approach for rapid, accurate docking and scoring.1. Method and assessment of docking accuracy. J Med Chem 47 : 1739 1749.
44. Halgren T.A., Murphy R.B., Friesner R.A., Beard H.S., Frye L.L., Pollard W.T., Banks J.L. (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47 : 1750 1759.
45. Jorgensen W.L., Maxwell D., Tirado-Rives J. (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118 : 11225 112236.
46. Hennequin L.F., Allen J., Breed J., Curwen J., Fennell M., Green T.P., Lambert-van der Brempt C. et al. (2006) N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2- (4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy) quinazolin-4amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem 49 : 6465 6488.
47. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Mainz D.T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K., Shaw D.E., Francis P., Shenkin P.S. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47 : 1739.
48. Halgren T.A., Murphy R.B., Friesner R.A., Beard H.S., Frye L.L., Pollard W.T., Banks J.L. (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47 : 1750.
49. Venkatachalam C.M., Jiang X., Oldfield T., Waldman M. (2003) LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 21 : 289.